Decentralized clinical trials are driving new complexities in data collection. T...
With the completed acquisition, Sanofi will gain access to SAR447537, Inhibrx’s ...
Royalty Pharma will receive 15% on US sales of vorasidenib, up to $1bn, and at a...
Several personalities, including a Nobel-winning scientist who helped discover H...
The company has fired 53% of its workforce and is shutting down the development ...
The cell and gene therapy market is accelerating in its evolution, as well as co...
The US BIOSECURE bill aims to prevent US companies from working with Chinese bio...
In May 2024, Italy’s medicines agency AIFA published a strategic overview, detai...
Asahi Kasei has made a public cash offer for the acquisition of all shares in Ca...
Helsinn Group has renewed an agreement with Angelini Pharma for the commercialis...
Scientists of QUT have secured A$4m ($2.65m) grant from the US DoD for developin...
Currently in a Phase IIa study, AV-001 is being co-developed with AnGes for the ...
Biomanufacturers using self-amplifying RNA, or saRNA, could enjoy significant ad...
Investor optimism in biotech has increased due to the expected lowering of inter...
J&J has made its second dermatology deal this month, adding Numab’s bispecific a...
Logistics service providers (LSPs) can help pharma companies achieve their suppl...
